Cell Cultures Sartorius and Refine Jointly Develop Cell Culture System
The use of equipment from different manufacturers often poses some challenges. Now two technology suppliers aim to combine their expertise in bioreactors and cell cultures for easy inter-operability.
Goettingen/Germany – Sartorius Stedim Biotech (SSB) and Refine Technology (Refine) join forces in an international development cooperation. The firms aim to develop a platform for high-density cell cultivation by using Refine's ATF System cell retention system in combination with the single use Biostat bioreactors of SSB, speakers said.
Sartorius regards this joint operation as a respond to the current market demand for more effective connectivity between equipment from different suppliers: “We decided to work together, based on market feedback, to create a better platform for late-stage clinical and commercial-scale biopharmaceutical manufacturing processes. Our objective is to give our customers the confidence of a well-thought-out system featuring optimal and robust high-density cell cultivation via perfusion and concentrated fed-batch processes,” stated Christel Fenge, Vice President of Fermentation Technologies at SSB.
John Bonham-Carter, Refine's Vice President of Sales and Business Development added: “The market demand for cell retention systems is expanding rapidly and we are pleased to be working with Sartorius Stedim Biotech to ensure that the ATF System integrates effortlessly with the Biotstat bioreactors. Our objective is to dramatically reduce the risk and cost of upstream processing through continuous culture and process intensification.”
As a first step, Sartorius Stedim Biotech and Refine are now providing users with initial application and protocol guidance for connecting the SSB single-use and reusable bioreactors and Refine’s ATF System on their website.